Disruption of the 5-lipoxygenase pathway attenuates atherogenesis consequent to COX-2 deletion in mice
Zhou Yu1, Irene Crichton, Soon Yew Tang
1Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Abstract:
Suppression of cyclooxygenase 2 (COX-2)-derived prostacyclin (PGI(2)) is sufficient to explain most elements of the cardiovascular hazard from nonsteroidal antinflammatory drugs (NSAIDs). However, randomized trials are consistent with the emergence of cardiovascular risk during chronic dosing with NSAIDs. Although deletion of the PGI(2) receptor fosters atherogenesis, the importance of COX-2 during development has constrained the use of conventional knockout (KO) mice to address this question. We developed mice in which COX-2 was deleted postnatally, bypassing cardiorenal defects exhibited by conventional KOs. When crossed into ApoE-deficient hyperlipidemic mice, COX-2 deletion accelerated atherogenesis in both genders, with lesions exhibiting leukocyte infiltration and phenotypic modulation of vascular smooth muscle cells, as reflected by loss of α-smooth muscle cell actin and up-regulation of vascular cell adhesion molecule-1. Stimulated peritoneal macrophages revealed suppression of COX-2-derived prostanoids and augmented 5-lipoxygenase product formation, consistent with COX-2 substrate rediversion. Although deletion of the 5-lipoxygenase activating protein (FLAP) did not influence atherogenesis, it attenuated the proatherogeneic impact of COX-2 deletion in hyperlipidemic mice. Chronic administration of NSAIDs may increasingly confer a cardiovascular hazard on patients at low initial risk. Promotion of atherogenesis by postnatal COX-2 deletion affords a mechanistic explanation for this observation. Coincident inhibition of FLAP may offer an approach to attenuating such a risk from NSAIDs.
Insights
Nonsteroidal anti-inflammatory drugs (NSAIDs) increase cardiovascular risk by suppressing cyclooxygenase 2 (COX-2). Postnatal COX-2 deletion in mice accelerated atherosclerosis, suggesting a mechanism for NSAID-related cardiovascular hazards.
Area of Science:
- Cardiovascular Science
- Inflammation Research
- Pharmacology
Background:
- Nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with cardiovascular risk, partly due to suppression of cyclooxygenase 2 (COX-2)-derived prostacyclin (PGI(2)).
- Conventional COX-2 knockout mice exhibit developmental defects, limiting their use in studying chronic NSAID effects.
- Understanding the role of COX-2 in atherogenesis is crucial for mitigating NSAID-induced cardiovascular hazards.
Purpose of the Study:
- To investigate the role of postnatal COX-2 deletion in promoting atherosclerosis.
- To elucidate the mechanistic link between COX-2 inhibition and cardiovascular risk associated with NSAID use.
Main Methods:
- Developed mice with postnatal deletion of COX-2 to bypass developmental issues.
- Crossed these mice with ApoE-deficient hyperlipidemic mice to study atherogenesis.
- Analyzed atherosclerotic lesions for leukocyte infiltration and vascular smooth muscle cell markers.
- Examined peritoneal macrophages for prostanoid and lipoxygenase product formation.
- Investigated the effect of 5-lipoxygenase activating protein (FLAP) deletion on atherogenesis.
Main Results:
- Postnatal COX-2 deletion accelerated atherosclerosis in hyperlipidemic mice, with increased leukocyte infiltration and altered vascular smooth muscle cell phenotype.
- COX-2 deletion led to suppressed COX-2-derived prostanoids and increased 5-lipoxygenase products in macrophages, indicating substrate rediversion.
- Deletion of FLAP did not affect atherogenesis but attenuated the pro-atherogenic effects of COX-2 deletion.
Conclusions:
- Postnatal COX-2 deletion promotes atherogenesis, providing a mechanistic explanation for the cardiovascular hazard of chronic NSAID use.
- The findings suggest that NSAIDs may increase cardiovascular risk, particularly in individuals with pre-existing low risk.
- Co-inhibition of FLAP may represent a strategy to mitigate NSAID-associated cardiovascular risks.
Related Concept Videos
Lipid Catabolism
Inflammation
Cholesterol: Significance and Regulation
Considering cholesterol and...
Lipid Digestion
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
TGF - β Signaling Pathway
